U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H33N5O4
Molecular Weight 539.626
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NINTEDANIB

SMILES

CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4N=C3O)C(=O)OC)/c5ccccc5

InChI

InChIKey=XZXHXSATPCNXJR-ZIADKAODSA-N
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-

HIDE SMILES / InChI

Molecular Formula C31H33N5O4
Molecular Weight 539.626
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/6-6-2016-boehringer-ingelheim-inventiva-collaborate-develop-potential-new-treatments-idiopathic-pulmonary-fibrosis.html

Nintedanib is a receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. It is the only kinase inhibitor drug approved to treat idiopathic pulmonary fibrosis. that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology.

CNS Activity

Curator's Comment:: Nintedanib (molecular weight 539 Da) does not cross the blood–brain barrier in normal rat brain (investigator’s brochure U03-1563), as is generally expected for molecules [300 Da].

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P17948|||B3FR89
Gene ID: 2321
Gene Symbol: FLT1
Target Organism: Homo sapiens (Human)
34 nM [IC50]
Target ID: P35968
Gene ID: 3791
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
21 nM [IC50]
Target ID: P35916
Gene ID: 2324
Gene Symbol: FLT4
Target Organism: Homo sapiens (Human)
13 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OFEV

Approved Use

Indicated for the treatment of idiopathic pulmonary fibrosis (IPF)

Launch Date

1413331200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.4 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.2 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.2%
NINTEDANIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Sources:
DLT: Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Sources:
250 mg 1 times / day steady, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: steady
Dose: 250 mg, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Sources:
DLT: Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (5%)
Nausea (2%)
Decreased appetite (2%)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Disc. AE: Weight decreased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Weight decreased (1.1%)
Alanine aminotransferase increased (0.6%)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Disc. AE: Vomiting, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Abdominal pain (1%)
Asthenia (0.7%)
Hepatic enzyme increased (0.6%)
Aspartate aminotransferase increased (0.4%)
Blood bilirubin increased (0.4%)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (10.9%)
Nausea (2.1%)
Decreased appetite (0.8%)
Weight decreased (0.6%)
Abdominal pain (0.8%)
Abdominal pain upper (0.8%)
Transaminases increased (0.4%)
Hepatic function abnormal (0.7%)
Sources:
250 mg 2 times / day steady, oral
MTD
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
DLT: Elevated liver enzymes...
Dose limiting toxicities:
Elevated liver enzymes (grade 3, 2 patients)
Sources:
600 mg 1 times / day multiple, oral
Overdose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Nasopharyngitis...
600 mg 2 times / day multiple, oral
Overdose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
AEs

AEs

AESignificanceDosePopulation
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Sources:
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
250 mg 1 times / day steady, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: steady
Dose: 250 mg, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Sources:
Decreased appetite 2%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Nausea 2%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Diarrhea 5%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Alanine aminotransferase increased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Weight decreased 1.1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Aspartate aminotransferase increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Blood bilirubin increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Hepatic enzyme increased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Asthenia 0.7%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Abdominal pain 1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Vomiting 1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Transaminases increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Weight decreased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Hepatic function abnormal 0.7%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Abdominal pain upper 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Abdominal pain 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Decreased appetite 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Diarrhea 10.9%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Nausea 2.1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
Health Status: unhealthy
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Sources:
Elevated liver enzymes grade 3, 2 patients
DLT
250 mg 2 times / day steady, oral
MTD
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Nasopharyngitis
600 mg 1 times / day multiple, oral
Overdose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 16 uM]
no [IC50 24.5 uM]
no [IC50 24.5 uM]
no [IC50 70.1 uM]
no [IC50 77.6 uM]
no [IC50 85.5 uM]
no [IC50 >200 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
yes [IC50 0.88 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: Coadministration with the P-gp and CYP3A4 inhibitor ketoconazole increased exposure of nintedanib by 1.61-fold based on AUC and 1.83-fold based on Cmax.
Page: 9
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
2008 Jun 15
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
2011 Apr
A new hope for idiopathic pulmonary fibrosis.
2014 May 29
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
2014 Sep
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
2015 Jul
Nintedanib in the treatment of idiopathic pulmonary fibrosis.
2015 Jun
Patents

Sample Use Guides

150 mg twice daily approximately 12 hours apart
Route of Administration: Oral
10-80 nmol/L resulted in 50% inhibition (EC50) of cell proliferation in human umbilical vascular endothelial cell HUVEC, microvascular skin endothelial cells HMSEC, umbilical artery smooth muscle cells HUASMC
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:33:07 UTC 2021
Edited
by admin
on Fri Jun 25 20:33:07 UTC 2021
Record UNII
G6HRD2P839
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NINTEDANIB
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BIBF1120
Code English
INTEDANIB
MI  
Common Name English
BIBF 1120
Code English
NINTEDANIB COMPONENT OF OFEV
Brand Name English
METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
Systematic Name English
NINTEDANIB [WHO-DD]
Common Name English
NINTEDANIB [VANDF]
Common Name English
NINTEDANIB [USAN]
Common Name English
INTEDANIB [MI]
Common Name English
BIBF-1120
Code English
OFEV COMPONENT NINTEDANIB
Brand Name English
NINTEDANIB [INN]
Common Name English
VARGATEF
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS OFEV (AUTHORISED: IDIOPATHIC PULMONARY FIBROSIS)
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
FDA ORPHAN DRUG 344511
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
WHO-ATC L01XE31
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
FDA ORPHAN DRUG 528516
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
EU-Orphan Drug EU/3/16/1724
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
FDA ORPHAN DRUG 547916
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
NCI_THESAURUS C1742
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
NCI_THESAURUS C155727
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
NDF-RT N0000175605
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
Code System Code Type Description
EVMPD
SUB120728
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
MERCK INDEX
M6301
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
4903
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
MESH
C530716
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
LACTMED
Nintedanib
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
CAS
656247-17-5
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
ChEMBL
CHEMBL502835
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
IUPHAR
5936
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
DRUG BANK
DB09079
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
RXCUI
1592737
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY RxNorm
HSDB
8339
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
FDA UNII
G6HRD2P839
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
NCI_THESAURUS
C62765
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
PUBCHEM
9809715
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
INN
9229
Created by admin on Fri Jun 25 20:33:07 UTC 2021 , Edited by admin on Fri Jun 25 20:33:07 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
The urinary excretion of unchanged nintedanib within 48 h was about 1% of dose after intravenous administration. The major route of excretion of total [14C]-radioactivity was via feces, demonstrated by a fecal excretion of 93.4% of dose within 120 hours.
URINE
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Vss PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC